[go: up one dir, main page]

HUE055056T2 - 1,2,4-oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére - Google Patents

1,2,4-oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére

Info

Publication number
HUE055056T2
HUE055056T2 HUE19174887A HUE19174887A HUE055056T2 HU E055056 T2 HUE055056 T2 HU E055056T2 HU E19174887 A HUE19174887 A HU E19174887A HU E19174887 A HUE19174887 A HU E19174887A HU E055056 T2 HUE055056 T2 HU E055056T2
Authority
HU
Hungary
Prior art keywords
disease
treatment
benzoic acid
acid compound
nonsense suppression
Prior art date
Application number
HUE19174887A
Other languages
English (en)
Inventor
Gary Mitchell Karp
Seongwoo Hwang
Guangming Chen
Neil Gregory Almstead
Young-Choon Moon
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of HUE055056T2 publication Critical patent/HUE055056T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE19174887A 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére HUE055056T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46198803P 2003-04-11 2003-04-11

Publications (1)

Publication Number Publication Date
HUE055056T2 true HUE055056T2 (hu) 2021-10-28

Family

ID=33299886

Family Applications (7)

Application Number Title Priority Date Filing Date
HUE17204895A HUE047569T2 (hu) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
HUE21169137A HUE059464T2 (hu) 2003-04-11 2004-04-09 1,2,4-Oxadiazolbenzoesav-vegyületek és ezek alkalmazása nonsense szuppresszióhoz és betegségek kezelésére
HUE19209758A HUE055434T2 (hu) 2003-04-11 2004-04-09 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére
HUE19174887A HUE055056T2 (hu) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére
HUE14188816A HUE031794T2 (hu) 2003-04-11 2004-04-09 1,2,4-oxadiol-benzoesav vegyületek és alkalmazásuk nonszensz szuppresszióra, valamint betegség kezelésére
HUE16170630A HUE039026T2 (hu) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesav vegyület és alkalmazása nonszensz szuppresszióra és betegség kezelésére
HUS1500021C HUS1500021I1 (hu) 2003-04-11 2015-04-16 1,2,4-oxadiazol-benzoesav vegyületek és alkalmazásuk nonszensz szupresszióra és a betegség kezelésére

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HUE17204895A HUE047569T2 (hu) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
HUE21169137A HUE059464T2 (hu) 2003-04-11 2004-04-09 1,2,4-Oxadiazolbenzoesav-vegyületek és ezek alkalmazása nonsense szuppresszióhoz és betegségek kezelésére
HUE19209758A HUE055434T2 (hu) 2003-04-11 2004-04-09 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE14188816A HUE031794T2 (hu) 2003-04-11 2004-04-09 1,2,4-oxadiol-benzoesav vegyületek és alkalmazásuk nonszensz szuppresszióra, valamint betegség kezelésére
HUE16170630A HUE039026T2 (hu) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesav vegyület és alkalmazása nonszensz szuppresszióra és betegség kezelésére
HUS1500021C HUS1500021I1 (hu) 2003-04-11 2015-04-16 1,2,4-oxadiazol-benzoesav vegyületek és alkalmazásuk nonszensz szupresszióra és a betegség kezelésére

Country Status (30)

Country Link
US (17) US6992096B2 (hu)
EP (9) EP2910551B1 (hu)
JP (2) JP4851933B2 (hu)
KR (1) KR101134188B1 (hu)
CN (2) CN104056278B (hu)
AU (1) AU2004229487B9 (hu)
BE (1) BE2015C025I2 (hu)
BR (1) BRPI0409319B8 (hu)
CA (1) CA2521992C (hu)
CR (1) CR8086A (hu)
CY (7) CY1115870T1 (hu)
DK (7) DK3549936T3 (hu)
EA (1) EA009120B1 (hu)
ES (7) ES2624610T3 (hu)
FR (1) FR15C0030I2 (hu)
HK (4) HK1093979A1 (hu)
HU (7) HUE047569T2 (hu)
IL (2) IL171343A (hu)
LU (1) LU92698I2 (hu)
MA (1) MA27802A1 (hu)
MX (1) MXPA05010747A (hu)
NO (2) NO332843B1 (hu)
NZ (1) NZ543263A (hu)
PL (7) PL3889142T3 (hu)
PT (7) PT3549936T (hu)
SI (7) SI3345895T1 (hu)
TR (1) TR201706226T4 (hu)
UA (1) UA84420C2 (hu)
WO (1) WO2004091502A2 (hu)
ZA (1) ZA200508298B (hu)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2004001010A2 (en) * 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
AU2003252136A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
CN104056278B (zh) 2003-04-11 2017-01-18 Ptc 治疗公司 1,2,4‑噁二唑苯甲酸化合物
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
MX2007004484A (es) 2004-10-13 2007-06-25 Ptc Therapeutics Inc Compuestos de pirazol o triazol y su uso para la fabricacion de un medicamento para tratar las enfermedades relacionadas con la mutacion somatica.
EP1874306B1 (en) * 2005-04-08 2012-07-04 PTC Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2012238226B2 (en) * 2005-04-08 2015-05-14 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CN100378084C (zh) * 2005-08-01 2008-04-02 安徽大学 2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途
CA2640013A1 (en) * 2006-02-09 2007-08-16 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US9289398B2 (en) * 2006-03-30 2016-03-22 Ptc Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
US20090221639A1 (en) * 2006-04-06 2009-09-03 Lisa Sarah Bertram Heterocyclic GPCR Agonists
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP2007756B1 (en) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US20070287699A1 (en) * 2006-05-01 2007-12-13 Virobay, Inc. Antiviral agents
RU2495030C2 (ru) * 2006-09-08 2013-10-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения 1,2,4-оксадиазолбензойных кислот
HUE028503T2 (hu) * 2006-09-25 2016-12-28 Ptc Therapeutics Inc 3-[5-(2-fluorfenil)-[1,2,4]oxadiazol-3-il]-benzoesav kristályos formái
WO2008130370A1 (en) 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
AU2013219243B2 (en) * 2006-10-12 2016-09-08 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2016262645B2 (en) * 2006-10-12 2018-05-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
KR20160128468A (ko) * 2006-10-12 2016-11-07 피티씨 테라퓨틱스, 인크. 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
JP2010513283A (ja) * 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US8283351B2 (en) * 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
JP5416103B2 (ja) * 2007-06-22 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾール−イミダゾール誘導体
WO2009013477A1 (en) * 2007-07-23 2009-01-29 Summit Corporation Plc Compounds for treating duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
TW200911237A (en) 2007-08-03 2009-03-16 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2699980C (en) 2007-08-13 2015-06-02 Divergence, Inc. Methods for the control of plant parasitic nematodes comprising application of oxadiazole compounds to plants, seeds or soil
AU2008306885B2 (en) * 2007-10-04 2013-12-05 Merck Serono S.A. Oxadiazole derivatives
US8404676B2 (en) 2007-10-04 2013-03-26 Merck Serono Sa Oxadiazole diaryl compounds
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
DK2217572T3 (da) 2007-11-16 2014-02-03 Vertex Pharma Isoquinoliner som modulatorer af ATP-bindingskassettetransportører
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
MX2010006202A (es) * 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CA2707669C (en) * 2007-12-07 2016-07-05 Wilfried Braje 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
ES2993060T3 (en) 2007-12-07 2024-12-20 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP5645217B2 (ja) 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
MX2010007026A (es) * 2007-12-21 2010-10-05 Merck Serono Sa Derivados de triazoloxadiazoles.
BRPI0821327A2 (pt) * 2007-12-25 2015-06-16 Kissei Pharmaceutical Derivado de catecol, composição farmacêutica contendo o mesmo, uso do derivado de catecol, e uso da composição farmacêutica
US8188131B2 (en) * 2008-02-07 2012-05-29 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
ES2442945T3 (es) 2008-03-31 2014-02-14 Vertex Pharmaceuticals Inc. Derivados de piridilo como moduladores del CFTR
WO2009131956A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
EP2278879B1 (en) * 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131954A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
KR101787112B1 (ko) * 2008-06-09 2017-11-15 루드비히-막시밀리안스-우니버지테트 뮌헨 신경변성 질환 및/또는 단백질 응집과 연관된 질환과 관련된 단백질의 응집을 억제하기 위한 신규 약물
EP2300442A2 (en) * 2008-06-24 2011-03-30 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
ES2542873T3 (es) 2009-02-10 2015-08-12 Monsanto Technology Llc Composiciones y procedimientos de control de nemátodos
JP5620129B2 (ja) * 2009-03-19 2014-11-05 富士フイルム株式会社 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2251437B1 (en) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US9849146B2 (en) * 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
PL2462276T3 (pl) * 2009-08-05 2015-04-30 Int Paper Co Dodatek do suchego arkusza z celulozowej masy puchowej
PH12012500938A1 (en) * 2009-11-13 2016-09-16 Receptos Llc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CA2986521C (en) 2009-11-13 2020-06-30 Celgene International Ii Sarl Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
RU2711481C2 (ru) 2010-03-25 2020-01-17 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
DK2555754T3 (en) 2010-04-07 2016-04-18 Vertex Pharma Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
EP3381899B1 (en) 2010-04-22 2021-01-06 Vertex Pharmaceuticals Incorporated Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2600865B1 (en) * 2010-08-05 2018-11-14 Université de Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
EP2608779A2 (en) 2010-08-23 2013-07-03 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR101314488B1 (ko) * 2011-09-08 2013-10-07 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
DK2806859T3 (da) 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
US9598395B2 (en) 2012-03-23 2017-03-21 The Regents Of The University Of California Premature-termination-codons readthrough compounds
KR102109223B1 (ko) 2012-05-29 2020-05-11 패리온 사이언스 인코퍼레이티드 안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드
UA114915C2 (uk) * 2012-07-02 2017-08-28 Монсанто Текнолоджи Ллс Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти)
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
SG11201503365YA (en) 2012-11-02 2015-06-29 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
AP2015008441A0 (en) 2012-12-13 2015-05-31 Novartis Ag Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors
US9029382B2 (en) 2012-12-17 2015-05-12 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
MX379300B (es) 2012-12-17 2025-03-11 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
EP3113619A4 (en) * 2014-03-06 2017-09-13 PTC Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CA2944140C (en) 2014-04-15 2022-10-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
ES2743184T3 (es) 2014-06-03 2020-02-18 Novartis Ag Derivados de pirimido[4,5-b]quinolin-4,5(3H,10H)-diona como supresores de mutaciones finalizadoras
WO2015186061A1 (en) 2014-06-03 2015-12-10 Novartis Ag Pyridopyrimidinedione derivatives
EA030374B1 (ru) 2014-06-03 2018-07-31 Новартис Аг Производные нафтиридиндиона
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
PL3203840T3 (pl) 2014-10-06 2021-01-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
CN104292180A (zh) * 2014-10-12 2015-01-21 湖南华腾制药有限公司 一种恶二唑衍生物的制备方法
US10174012B2 (en) 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
WO2016073545A1 (en) * 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
US9994559B2 (en) 2014-12-17 2018-06-12 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
BR112018008838A8 (pt) 2015-10-30 2019-02-26 Ptc Therapeutics Inc método para tratar, prevenir, melhorar ou administrar uma doença epiléptica
EP3377476B1 (en) * 2015-11-16 2022-10-26 PTC Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
EP3405587A4 (en) 2015-12-23 2019-10-30 Moonshot Pharma LLC METHOD FOR TRIGGERING AN IMMUNE REACTION THROUGH READ THROUGH PROMOTION OF A PREVIOUS TERMINATION CODON
TW201808922A (zh) * 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
CN106279057B (zh) * 2016-08-15 2022-04-15 广州明药科技有限公司 Ataluren的合成方法
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
US11207300B2 (en) 2016-09-13 2021-12-28 Marco Cipolli Method of treatment of Shwachman-diamond syndrome
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
WO2020078894A1 (en) 2018-10-15 2020-04-23 Academisch Medisch Centrum Oncotherapeutic combinations
KR102658031B1 (ko) 2018-12-27 2024-04-18 제이투에이치바이오텍 (주) 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체
WO2020210432A1 (en) 2019-04-10 2020-10-15 Ptc Therapeutics, Inc. Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN111675672A (zh) * 2020-05-12 2020-09-18 石家庄市度智医药科技有限公司 一种制备阿塔鲁伦的方法
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
CN116217508B (zh) * 2022-12-15 2024-12-17 浙江工业大学 一类用于保护β细胞来治疗II型糖尿病的噁二唑类化合物及其制备方法和应用
US11932632B1 (en) 2023-10-13 2024-03-19 King Faisal University N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound
US11958814B1 (en) 2023-11-02 2024-04-16 King Faisal University 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (hu) * 1962-04-17
US3325446A (en) 1964-04-17 1967-06-13 Allied Chem Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en) 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) * 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4135910A (en) * 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4165910A (en) * 1977-10-25 1979-08-28 Bunker Ramo Corporation Electrical connector
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4268299A (en) * 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) * 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
DE3173083D1 (en) 1980-03-22 1986-01-16 Fbc Ltd Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4320801A1 (de) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6071700A (en) * 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
US5970974A (en) 1995-03-14 1999-10-26 Siemens Aktiengesellschaft Dosating unit for an ultrasonic atomizer device
ES2140069T3 (es) 1995-03-14 2000-02-16 Siemens Ag Dispositivo atomizador ultrasonico con unidad dosificadora de precision desmontable.
IL123191A0 (en) 1995-09-07 1998-09-24 Novartis Ag Substituted phosphinic compounds and their use as pharmaceuticals
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
CN1216534A (zh) * 1996-04-26 1999-05-12 日本曹达株式会社 杂环取代的新颖苯衍生物和除草剂
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US6034106A (en) * 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
CA2257206A1 (en) 1996-06-07 1997-12-11 Gui-Bai Liang Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
ES2329739T3 (es) * 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
WO1999021852A1 (fr) * 1997-10-27 1999-05-06 Nippon Soda Co., Ltd. Nouveaux derives de benzoylpyrazole et herbicides
CN1292714B (zh) 1998-03-16 2012-08-01 诺瓦帝斯公司 气溶胶化活性剂的输送
CA2329712A1 (en) 1998-04-23 1999-10-28 Cortech Inc. Cysteine protease inhibitors
CZ20011270A3 (cs) 1998-10-08 2001-09-12 Smithkline Beecham Plc Tetrahydrobenzazepinové deriváty vhodné jako modulátory dopaminových receptorů D3
CA2346396C (en) 1998-10-09 2009-04-28 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
AU1455500A (en) 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
DE69939752D1 (de) * 1998-12-23 2008-11-27 Smithkline Beecham Corp 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors
WO2000058304A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives sulfonamides heterocycliques
WO2000058280A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives de sulfonamide carbocyclique
WO2000058278A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. β-AMINO ACID DERIVATIVES
CZ20013767A3 (cs) 1999-05-17 2002-04-17 Novo Nordisk A/S Sloučenina, farmaceutický prostředek, pouľití sloučeniny a způsob léčení
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
AU2001243987A1 (en) * 2000-03-22 2001-10-03 Merck Frosst Canada & Co. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
AU2001248765A1 (en) * 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
KR100858642B1 (ko) 2000-05-22 2008-09-17 아벤티스 파마슈티칼스 인크. 트립타제 억제제로서 사용하기 위한 아릴메틸아민 유도체
CN1328143A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人甲基化－dna－蛋白－半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
JP4480941B2 (ja) 2001-04-19 2010-06-16 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト 抗ウイルス剤としての新規アリールスルホンアミド
MXPA03011196A (es) * 2001-06-08 2004-10-28 Cytovia Inc 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos.
JP2003081832A (ja) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
CA2495120A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
JP2006521344A (ja) 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
CN104056278B (zh) * 2003-04-11 2017-01-18 Ptc 治疗公司 1,2,4‑噁二唑苯甲酸化合物
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
MX2007004484A (es) 2004-10-13 2007-06-25 Ptc Therapeutics Inc Compuestos de pirazol o triazol y su uso para la fabricacion de un medicamento para tratar las enfermedades relacionadas con la mutacion somatica.
EP1874306B1 (en) * 2005-04-08 2012-07-04 PTC Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US9289398B2 (en) 2006-03-30 2016-03-22 Ptc Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
RU2495030C2 (ru) 2006-09-08 2013-10-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения 1,2,4-оксадиазолбензойных кислот
HUE028503T2 (hu) 2006-09-25 2016-12-28 Ptc Therapeutics Inc 3-[5-(2-fluorfenil)-[1,2,4]oxadiazol-3-il]-benzoesav kristályos formái
KR20160128468A (ko) 2006-10-12 2016-11-07 피티씨 테라퓨틱스, 인크. 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
AU2008306885B2 (en) 2007-10-04 2013-12-05 Merck Serono S.A. Oxadiazole derivatives
EP2614827B1 (en) 2007-10-26 2017-06-28 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
ES2594302T3 (es) 2007-12-17 2016-12-19 The Regents Of The University Of Michigan Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético
EP2300442A2 (en) 2008-06-24 2011-03-30 Irm Llc Compounds and methods for modulating g protein-coupled receptors
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота

Also Published As

Publication number Publication date
US7772259B2 (en) 2010-08-10
JP2006522826A (ja) 2006-10-05
EP3345895B1 (en) 2019-12-04
DK3345895T3 (da) 2020-02-03
PT3889142T (pt) 2022-08-22
HK1257517A1 (zh) 2019-10-25
US8796322B2 (en) 2014-08-05
DK3889142T3 (da) 2022-09-12
IL171343A (en) 2013-06-27
EP3632902B1 (en) 2021-07-14
US20120178080A1 (en) 2012-07-12
ZA200508298B (en) 2007-01-31
CY1120446T1 (el) 2019-07-10
HK1093979A1 (en) 2007-03-16
KR101134188B1 (ko) 2012-04-12
UA84420C2 (ru) 2008-10-27
US6992096B2 (en) 2006-01-31
CN1802360B (zh) 2014-05-07
PL3549936T3 (pl) 2021-11-08
SI2910551T1 (sl) 2017-07-31
US20160081988A1 (en) 2016-03-24
NO20055314L (no) 2006-01-04
US7304080B2 (en) 2007-12-04
EP3549936A1 (en) 2019-10-09
EP4101846A1 (en) 2022-12-14
HUE059464T2 (hu) 2022-11-28
BRPI0409319A (pt) 2006-04-25
EP1618098A2 (en) 2006-01-25
NO332843B1 (no) 2013-01-21
US7683082B2 (en) 2010-03-23
HUE047569T2 (hu) 2020-04-28
EP1618098A4 (en) 2008-07-16
ES2624610T3 (es) 2017-07-17
CY1122659T1 (el) 2020-10-14
PT3632902T (pt) 2021-09-15
EP3889142A1 (en) 2021-10-06
US20060148864A1 (en) 2006-07-06
BE2015C025I2 (hu) 2023-08-09
ES2528195T3 (es) 2015-02-05
US9205088B2 (en) 2015-12-08
US9861617B2 (en) 2018-01-09
EP3103800A1 (en) 2016-12-14
EP2910551A1 (en) 2015-08-26
PT3549936T (pt) 2021-07-14
ES2679108T3 (es) 2018-08-22
JP2011251981A (ja) 2011-12-15
DK3632902T3 (da) 2021-09-13
WO2004091502A3 (en) 2004-12-29
US7419991B2 (en) 2008-09-02
EP3632902A1 (en) 2020-04-08
CY2015017I2 (el) 2016-06-22
AU2004229487A1 (en) 2004-10-28
FR15C0030I2 (fr) 2015-07-24
US20070161687A1 (en) 2007-07-12
AU2004229487B9 (en) 2010-06-10
US20100216851A1 (en) 2010-08-26
MXPA05010747A (es) 2006-05-25
AU2004229487B2 (en) 2010-05-20
SI1618098T1 (sl) 2015-04-30
CN104056278A (zh) 2014-09-24
EA200501601A1 (ru) 2006-06-30
US20100121070A1 (en) 2010-05-13
JP5436500B2 (ja) 2014-03-05
JP4851933B2 (ja) 2012-01-11
NO2015002I1 (no) 2015-02-16
WO2004091502A8 (en) 2005-11-24
DK2910551T3 (en) 2017-05-15
US20060035943A1 (en) 2006-02-16
HUE055434T2 (hu) 2021-11-29
CY1124464T1 (el) 2022-07-22
PL3889142T3 (pl) 2022-09-26
EP1618098B1 (en) 2014-11-19
US20140301978A1 (en) 2014-10-09
HK1214253A1 (zh) 2016-07-22
CY1115870T1 (el) 2016-06-22
US10071081B2 (en) 2018-09-11
CY1125544T1 (el) 2024-09-20
DK1618098T3 (en) 2015-01-12
KR20060009838A (ko) 2006-02-01
WO2004091502A2 (en) 2004-10-28
NO20055314D0 (no) 2005-11-10
US8975287B2 (en) 2015-03-10
HK1202254A1 (en) 2015-09-25
SI3103800T1 (sl) 2018-10-30
EP3889142B1 (en) 2022-06-15
LU92698I2 (fr) 2015-06-22
HUE039026T2 (hu) 2018-12-28
NZ543263A (en) 2008-12-24
BRPI0409319B1 (pt) 2019-11-12
FR15C0030I1 (hu) 2015-05-22
US8129540B2 (en) 2012-03-06
PT3345895T (pt) 2020-01-29
US8163782B2 (en) 2012-04-24
US20040204461A1 (en) 2004-10-14
NO2015002I2 (no) 2015-02-03
HUS1500021I1 (hu) 2017-04-28
CN104056278B (zh) 2017-01-18
EP4101846B1 (en) 2023-08-02
PL3632902T3 (pl) 2021-12-20
US8017636B2 (en) 2011-09-13
US20130289007A1 (en) 2013-10-31
SI3549936T1 (sl) 2021-09-30
US20120277234A1 (en) 2012-11-01
US20050164973A1 (en) 2005-07-28
US20150148346A1 (en) 2015-05-28
US8486982B2 (en) 2013-07-16
PT2910551T (pt) 2017-05-22
US20060148863A1 (en) 2006-07-06
US20100168109A1 (en) 2010-07-01
SI3632902T1 (sl) 2022-01-31
HUE031794T2 (hu) 2017-08-28
SI3345895T1 (sl) 2020-03-31
US7202262B2 (en) 2007-04-10
PT3103800T (pt) 2018-07-27
US8299105B2 (en) 2012-10-30
CA2521992A1 (en) 2004-10-28
PL3103800T3 (pl) 2018-11-30
CR8086A (es) 2006-12-19
EP3178816A1 (en) 2017-06-14
CN1802360A (zh) 2006-07-12
EP3103800B1 (en) 2018-06-13
US20180092887A1 (en) 2018-04-05
SI3889142T1 (sl) 2022-10-28
CY2015017I1 (el) 2016-06-22
EP3549936B1 (en) 2021-06-02
PL1618098T3 (pl) 2015-04-30
PL2910551T3 (pl) 2017-09-29
EP3345895A1 (en) 2018-07-11
EA009120B1 (ru) 2007-10-26
CA2521992C (en) 2013-02-05
DK3103800T3 (en) 2018-07-30
EP2910551B1 (en) 2017-02-15
BRPI0409319B8 (pt) 2021-05-25
CY1119001T1 (el) 2018-01-10
ES2881198T3 (es) 2021-11-29
US20110311486A1 (en) 2011-12-22
ES2887054T3 (es) 2021-12-21
MA27802A1 (fr) 2006-03-01
ES2926542T3 (es) 2022-10-26
ES2770035T3 (es) 2020-06-30
PT1618098E (pt) 2015-02-10
TR201706226T4 (tr) 2018-06-21
PL3345895T3 (pl) 2020-05-18
US8227494B2 (en) 2012-07-24
IL225161A (en) 2014-03-31
DK3549936T3 (da) 2021-07-12

Similar Documents

Publication Publication Date Title
HK1257517A1 (zh) 1，2，4-噁二唑苯甲酸化合物及其在無義抑制和疾病治療中的用途
AU2003254157A8 (en) Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL196301A0 (en) Medicament for the treatment of hapatitis c
EP1485127A4 (en) ADMINISTRATION OF AGENTS FOR THE TREATMENT OF IGNITION
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
HK1073313A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PL375627A1 (en) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
IL165851A0 (en) The use of benziselenazolone compounds in the preparation of medicament against ischemic myocardial injury
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
GB0212790D0 (en) Medicament for the treatment of diabetes
GB0315877D0 (en) Compounds for the treatment of disease
GB0223996D0 (en) Pharmaceutical formulation for the treatment of cardiovascular disease